Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab in Postmenopausal Women With Osteoporosis
2011-001456-11Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing Romosozumab arm with Placebo arm (2 arms). Primary endpoint: Primary efficacy and safety endpoints over 12 months. Started Mar 2012; status: completed.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2011-001456-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001456-11.